How to Cite
Abstract
Polycystic ovary syndrome (PCOS) significantly increases the risk of metabolic syndrome (MetS), requiring early detection of insulin resistance and central obesity for effective prevention [1]. A cross-sectional study found that IDF criteria offer superior sensitivity over ATP III for diagnosing early metabolic abnormalities, with HOMA-IR and waist circumference as key indicators [1]. For more details, visit the study's abstract.
References
1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81(1), 19–25.
2. Alberti, K. G., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine, 23(5), 469–480.
3. National Cholesterol Education Program (NCEP) Expert Panel. (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106(25), 3143.
4. Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews, 33(6), 981–1030.